148 completed, 47 terminated, 33 recruiting, 20 active not recruiting. 279 Phase 2, 66 Phase 1, 5 Phase 3.
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis bomedemstat - Myelofibrosis | Phase 2 | Not yet recruiting | United Lincolnshire Hospitals NHS Trust | 40 | 2026-11-01 | 2026-02-20 |
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera | Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-11-01 | 2026-10-16 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 10 | 2026-10-15 | 2026-10-28 |
| A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis TQ05105 Tablets (Rovadicitinib Tablets) - Myelofibrosis | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 51 | 2026-06-18 | 2026-07-15 |
| Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis Luspatercept, Control - Luspatercept, Poor Erythroid Engraftment | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 196 | 2026-05-01 | 2026-04-20 |
| Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia Pacritinib - Myelofibrosis，MF | Phase 2 | Recruiting | Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas | 30 | 2026-04-15 | 2026-10-02 |
| Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis Gecacitinib (also known as Jaktinib) - Myelofibrosis (MF), HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 39 | 2026-03-16 | 2026-03-13 |
| Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan - Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-02-04 | 2026-10-19 |
| Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) Axatilimab (SNDX-6352), Ruxolitinib - Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 66 | 2026-01-02 | 2026-10-09 |
| A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors Roginolisib - Myelofibrosis (MF) | Phase 1 / Phase 2 | Recruiting | iOnctura | 26 | 2025-11-17 | 2026-06-23 |
| Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow Nelfinavir - Myelofibrosis, Myelofibrosis; Anemia | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 10 | 2025-09-16 | 2026-10-26 |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-10-27 |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C - AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL) | Phase 2 | Recruiting | Center for International Blood and Marrow Transplant Research | 358 | 2025-07-25 | 2026-03-17 |
| Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis Ropeginterferon alfa-2b (BESREMi®) - Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF) | Phase 2 | Recruiting | The University of Hong Kong | 20 | 2025-03-01 | 2025-06-11 |
| Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis Momelotinib, Luspatercept - Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Recruiting | GlaxoSmithKline | 68 | 2025-02-28 | 2026-04-20 |
| Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition Tasquinimod - Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 20 | 2025-02-20 | 2025-03-07 |
| A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis Ulixertinib, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 37 | 2025-01-07 | 2026-07-28 |
Showing 20 of 279. Sign in to see all of them.
Myeloproliferative Disorders (111) · Myelodysplastic Syndromes (93) · Leukemia, Myeloid, Acute (88) · Polycythemia Vera (80) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (77) · Leukemia, Lymphocytic, Chronic, B-Cell (76) · Multiple Myeloma (67) · Leukemia (66) · Thrombocythemia, Essential (64) · Leukemia, Myelomonocytic, Chronic (63) · Lymphoma, Non-Hodgkin (60) · Hodgkin Disease (59) · Leukemia, Myeloid, Chronic-Phase (53) · Lymphoma, Follicular (53)
Hemic and Lymphatic Diseases (279) · Bone Marrow Diseases (274) · Hematologic Diseases (270) · Myeloproliferative Disorders (168) · Neoplasms (157) · Neoplasms by Histologic Type (124) · Pathological Conditions, Signs and Symptoms (114) · Leukemia, Myeloid (111) · Neoplasms by Site (110) · Pathologic Processes (110) · Disease Attributes (108) · Hemorrhagic Disorders (108) · Chronic Disease (106) · Immune System Diseases (99) · Immunoproliferative Disorders (93)
ruxolitinib (52) · Cyclophosphamide (43) · fludarabine phosphate (39) · Tacrolimus (35) · Busulfan (33) · Peripheral Blood Stem Cell Transplantation (30) · Mycophenolic Acid (25) · Whole-Body Irradiation (25) · Methotrexate (22) · Antilymphocyte Serum (21) · fludarabine (19) · Melphalan (17) · Cyclosporine (15) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (11) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (10)
M.D. Anderson Cancer Center (27) · Fred Hutchinson Cancer Center (24) · Incyte Corporation (12) · City of Hope Medical Center (10) · John Mascarenhas (9) · National Cancer Institute (NCI) (9) · Novartis Pharmaceuticals (7) · Masonic Cancer Center, University of Minnesota (6) · Mayo Clinic (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Sierra Oncology LLC - a GSK company (5) · Bristol-Myers Squibb (4) · Case Comprehensive Cancer Center (4) · Kartos Therapeutics, Inc. (4) · Northside Hospital, Inc. (4)
United States (218) · Italy (40) · Germany (33) · France (27) · Canada (25) · Spain (25) · Australia (23) · United Kingdom (23) · Belgium (15) · Poland (15) · South Korea (13) · Israel (12) · China (11) · Netherlands (10) · Taiwan (9)
John Mascarenhas, MD (9) · Ayalew Tefferi, MD (5) · Ronald Hoffman, MD (4) · Ruben A. Mesa, MD (4) · Ryotaro Nakamura, MD (4) · Alessandro Rambaldi, MD (3) · Jorge Cortes, MD (3) · Prithviraj Bose (3) · Rachel B. Salit (3) · Srdan Verstovsek, MD (3) · Uday Popat, MD (3) · Albert Assad, MD (2)
PMID 31527168, PMID 32499241, PMID 41758981, PMID 10204198, PMID 11468154, PMID 18451242, PMID 18997171, PMID 19451433, PMID 19706886, PMID 19720904, PMID 19812383, PMID 19841031, PMID 20008298, PMID 20124511, PMID 20424252, PMID 20651074, PMID 20709666, PMID 20843246, PMID 21742281, PMID 21874061, PMID 22718840, PMID 22766223, PMID 23701016, PMID 23812932, PMID 24327518, PMID 24355079, PMID 24362550, PMID 24963042, PMID 25563429, PMID 25762180, PMID 26088933, PMID 26210442, PMID 26332545, PMID 27424289, PMID 27479177, PMID 27634203, PMID 27658437, PMID 27736729, PMID 27760761, PMID 27789678, PMID 27801315, PMID 27931243, PMID 28096091, PMID 28672195, PMID 29073967, PMID 29134664, PMID 29383130, PMID 29419434, PMID 29515114, PMID 29544547
P01CA108671 (7), 2017 (6), P30CA015083 (5), P30CA015704 (4), P30CA033572 (4), 2015 (3), 2023 (3), P01CA015396 (3), P30CA006973 (3), 2018 (2), N01CM62201 (2), P30CA014599 (2), P30CA016058 (2), P30CA016086 (2), P30CA016672 (2)